	not require routing to the CDC Huma	proposals to the LSPP an Research Protectio	PO ADS Office fo n Office at this tim	PPPO ADS Office or determination that have not begun and do ne. Projects eligible for this classification are man subjects; (3) human subject research i
Project Title: Cytolog	gy Workload Assessment a	and Measure		
Project Location/Cour	try(ies): USA			
Project Officer(s): Ma	riBeth Gagnon	Division: DLSS	3	Telephone: 404 498-2745
a contrast to the end of the first	and successive production with Association			mangala in televia kabacijué to betruktur
	es: Start: August 31, 2013		End: August	30, 2015
Please check appropriate of	ategory and subcategory:			
A. Epi provid B. Rou C. Pro	human subjects research. Priman demic or endemic disease control a e Epi-Aid number & documentation utine disease surveillance activity; d gram evaluation activity; data are u	activity; collected data of request for assista lata used for disease sed primarily for that	a directly relate to ance, if division p control program purpose.	disease control (e.g. Epi-Aids; olicy). Epi-Aid # or policy purposes.
	st-marketing surveillance of effective	eness or adverse effe	ects of a new regi	men, drug, vaccine, or device.
	oratory proficiency testing. t human subjects research. Pr	rimary intent is pub	lic health progra	am activities
A. Put progra assess	olic health program activity (e.g., ser im monitoring; electronic database o	rvice delivery; health construction and/or s	education progra upport; developm	ims; social marketing campaigns;
B. Act	ivity is purely administrative (e.g., p	urchase orders or co	ntracts for service	es or equipment).
which B. Act	ivity is research involving collection are not individual persons. ivity is research involving data or sp ivity is research using unlinked or an 1. No contact with human subjec	becimens from decea nonymous data or sp	sed persons. ecimens: <u>ALL</u> (1	-4) of the following are required:
Andrew of several party	2. Data or specimens are/were c	Decomposition and the second second second second		
and insure a second second	3. No extra data/specimens are/	and the second sec		of the business in his borters respective
	4. Identifying information was: (o	ne of these must be	спескеа)	
	<b>—</b>		to CDC receipt, s	that data cannot be linked or re-
		ects enter into an agr	eement prohibitir	the holder of the key linking the data to ng the release of the key to the ent must be attached).
	nrch involving human subjects but ne option below: 'A' indicates the pro			itute "engagement in human subject is <u>no</u> current funding
	s project is funded under a grant/coo f the following 3 elements are requi	red:		
	1. CDC employees or agents will		-	
	<ol> <li>CDC employees or agents will</li> <li>Supported institution must hav registered IRB linked to the supp Supported Institution/Entity Name Supported Institution/Entity FWA</li> </ol>	ve a Federalwide Ass ported institution's FW e: .#	urance (FWA) ar VA. FWA E	
		at does not involve po	ossession or anal	lysis of identifiable data or interaction with
	cipants from whom data are being collected (No current CDC funding). DC staff are involved only in manuscript writing for a project that has closed. For the project, CDC staff did not			

C. CDC staff are involved only in manuscript writing for a project that has closed. For the project, CDC staff did not interact with participants and were not involved with data collection (No current CDC funding).

Although CDC IRB review is not required for projects approved under this determination, CDC investigators and project officers are expected to adhere to the highest ethical standards of conduct and to respect and protect to the extent possible the privacy, confidentiality, and autonomy of participants. All applicable Country, State, and Federal privacy laws must be followed.

Although this project may not constitute "research" involving human subjects, informed consent may be appropriate. Information conveyed in an informed consent process should address all applicable required elements of informed consent.

#### **Definitions and Links**

OHRP defines *research* as a systematic investigation, including research development, testing and evaluation, designed to develop or contribute to generalizable knowledge. Activities which meet this definition constitute research, whether or not these activities are conducted or supported under a program which is considered research for other purposes. For example, some demonstration and service programs may include research activities. <u>http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm#46.102</u>

OHRP defines a human subject as a living individual about whom an investigator (whether professional or student) conducting research obtains

- (1) Data through intervention or interaction with the individual, or
- (2) Identifiable private information.

Intervention includes both physical procedures by which data are gathered (for example, venipuncture), and manipulations of the subject or the subject's environment that are performed for research purposes. Interaction includes communication or interpersonal contact between investigator and subject. *Private information* includes information about behavior that occurs in a context in which an individual can reasonably expect that no observation or recording is taking place, and information which has been provided for specific purposes by an individual and which the individual can reasonably expect will not be made public (for example, a medical record). Private information must be individually identifiable (i.e., the identity of the subject is or may readily be ascertained by the investigator or associated with the information) in order for obtaining the information to constitute research involving human subjects. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm#46.102

OHRP considers that an institution becomes "engaged" in human subjects research when its employees or agents intervene or interact with living individuals for research purposes; or (ii) obtain individually identifiable private information for research purposes. An institution is automatically considered to be "engaged" in human subjects research whenever it receives a direct HHS award to support such research. In such cases, the awardee institution bears ultimate responsibility for protecting human subjects under the award. http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html. **Agents** include all individuals performing institutionally designated activities or exercising institutionally delegated authority or responsibility, e.g., contractors.

CDC defines *surveillance* as "the ongoing, systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice, closely integrated with the timely dissemination of these data to those who need to know. The final link of the surveillance chain is the application of these data to prevention and control. A surveillance system includes a functional capacity for data collection, analysis, and dissemination linked to public health programs." (CDC 1986)

**Program evaluation** is the systematic collection of information about the activities, characteristics, and outcomes of programs to make judgments about the program, improve program effectiveness, and/or inform decisions about future program development. Program evaluation should not be confused with *treatment efficacy* which measures how well a treatment achieves its goals which can be considered as research. CDC guidance on research/non-research <a href="http://www.cdc.gov/od/science/regs/hrpp/researchDefinition.htm">http://www.cdc.gov/od/science/regs/hrpp/researchDefinition.htm</a>

For easy access to HHS human subjects regulations, see <u>http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm</u> For guidance on differentiating research from nonresearch, see <u>http://www.cdc.gov/od/science/regs/hrpp/researchDefinition.htm</u> For guidance on engagement of institutions in research, see <u>http://www.hhs.gov/ohrp/humansubjects/guidance/engage08.html</u>

Attach protocol or project description (standard format at end of this form) in enough detail to justify the proposed category. Submit through division ADS/Director.

Check here if an OMB determination form has been completed for this project.

Check here if this request is an **amendment** to an existing project determination. \* Please include a brief description of the substantive change or modification below and attach both clean and marked copies of the amended protocol or project outline.

Brief Description of change/modification:

Revised 07/15/2009

Approval initials & printed name: Manual Manua		Division ADS of Division Director Date
Division Notes/Comments:		
		, Principal Inventigator(s): Marillon Degram
Project Title:		
LSPPPO ADS Review Date received in	LSPPPO ADS office:	
Concur; project does not require hum	an subject research review b	beyond LSPPPO at this time
Project constitutes human subject res	search that must be routed to	
Comments/Rationale for Determine	nation:	
		(6. Plane for publication and discrimination of file p coreat
Signed: <u>Shambar</u> & Name Associate Director for Science, LSPPF	ibberlen 0	01/31/2013 Date
		hilp://www.cytoput/totogy.org/website/totototototototo

NOTE: This page is an outline for a proposal to ensure all required information is included for review and approval. You may submit a proposal following the outline provided below, or a full protocol that includes information pertaining to all applicable elements.

PROJECT TITLE: Cytology Workload Assessment and Measure

1. Principal Investigator(s): MariBeth Gagnon

2. CDC Project Officer(s) including roles and responsibilities: MariBeth Gagnon, collaborate with awardee

3. Other participants in research: N/A

4. Sponsoring institution(s): CDC/OSELS/LSPPPO/DLSS

5. Project Goals: Provide information on cytology workload assessment and measures to HHS agencies responsible for the Clinical Laboraotry Improvement Amendment (CLIA) program to determine appropriate gynecologic cytology screening workload maximums using semi-automated screening devices.

6. Project Objectives: 1) Conduct an assessment of practice related to cytology workload for cytotechnologists and 2) measure the amount of time spent by cytotechnologsits screening Pap test glass slides using an automated review microscope with the two FDA approved semi-autoamted screening systems.

7. Program needs to be addressed: Provide information on cytology workload assessment and measures to HHS agencies responsible for the Clinical Laboratory Improvement Amendment (CLIA) program to determine appropriate gynecologic cytology screening workload maximums using semi-automated screening devices.

8. Populations to be studied: CLIA-certified cytology laboratories in the US

9. Methods: survey and time study

10. Sampling Methodology: 100 participants will be selected to include a mix of different types of laboratories (independent and hospital), different sizes of laboratories (small, medium, and large) and include individuals that screen slides at various speeds.

11. Incentives to be provided: N/A

12. Plans for data collection and analysis: To be determined in collaboration with contract awardee

13. Confidentiality protections: No confidential infomration will be collected.

14. Other ethical concerns/issues: N/A

15. Projected time frame for the project: August 31, 2013 - August 30, 2015

16. Plans for publication and dissemination of the project findings: Results will be published in a peer-reviewed journal

17. Appendices - including informed consent documents, data collection instruments, focus group guides, flyers, etc: Survey will be developed and cleared through OMB

**18. References:** ASC's Workload Recommendation for Automated Pap Test Screening. http://www.cytopathology.org/website/download.asp?id=6429

February 2012 CLIAC Summary, see section on Semi-Automated Cytology Workload,

http://wwwn.cdc.gov/cliac/cliac0212.aspx

September 2010 CLIAC Summary, see section on Workload Recording for Semi-automated Cytology Screening Devices (FDA) under Cytology Proficiency Testing, http://wwwn.cdc.gov/cliac/cliac0910.aspx

BD FocalPoint<sup>™</sup> GS Imaging System Product Insert,

http://www.bd.com/tripath/downloads/msds\_pi/focalpoint/focalpoint\_gs\_pi.pdf

Thin Prep Imaging product insert, http://www.thinprep.com/pdfs/thinprep\_package\_insert.pdf